SMMT Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.